Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAKWATER first-line encorafenib + cetuximab with or without chemotherapy versus standard of care in metastatic BRAF V600E-mutant colorectal cancer
jRCT2031200393Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of encorafenib and cetuximab in colorectal cancer (CRC) (5 arms), sponsored by Pfizer. Primary endpoints: Incidence of dose limiting toxicities, Progression-free survival by blinded independent review and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031200393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200393.